Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Dollar Steadies Ahead of ECB and BoE Decisions as Markets Turn Risk-Off 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Thailand Inflation Remains Negative for 10th Straight Month in January 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal 
India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out 
Pfizer inc., an American pharmaceutical and biotechnology firm headquartered in Manhattan, New York City, has agreed to buy Global Blood Therapeutics biotech company for $5.4 billion. The drugmaker will be paying $68.50 a share for the acquisition.
According to Reuters, Pfizer will purchase the blood disorder medicine producer as it would like to bolster its drug lineup to counter or fight a possible slowdown in the demand for COVID medicines and other products since the cases are starting to fall.
Pfizer was one of the drugmakers that earned the most at the height of the COVID-19 pandemic since it supplied the vaccines around the world. With most people worldwide now fully vaccinated, the company is now looking for acquisitions that will bring in profits annually
Pfizer confirmed on Monday, Aug. 8, that it will be paying $68.50 per share to buy Global Blood Therapeutics. This amount is equivalent to a premium of around 7.3% to the stock's closing price last Friday.
Following the announcement of the deal with Pfizer, the shares of Global Blood reportedly soared by 4.5%. The company is known for its blood disorder drug called Oxbryta, which was first approved in 2019.
It is used for the treatment of sickle cell disease in patients who are 12 years old or older. In December 2021, it was also approved for the treatment of younger patients who are suffering from the said disease.
“Sickle cell disease is the most common inherited blood disorder, and it disproportionately affects people of African descent. We are excited to welcome GBT colleagues into Pfizer and to work together to transform the lives of patients, as we have long sought to address the needs of this underserved community,” Pfizer’s chairman and chief executive officer, Albert Bourla, said in a press release.
He added, “The deep market knowledge and scientific and clinical capabilities we have built over three decades in rare hematology will enable us to accelerate innovation for the sickle cell disease community and bring these treatments to patients as quickly as possible.”
